melatonin has been researched along with Parkinson Disease, Secondary in 13 studies
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment of melatonin protected against nigral dopamine loss and replenished the striatal dopamine loss that resulted in amelioration of rotational behavioral bias in Hcy denervated animals." | 1.48 | Melatonin protects against behavioral deficits, dopamine loss and oxidative stress in homocysteine model of Parkinson's disease. ( Bhattacharya, P; Borah, A; Justin Thenmozhi, A; Manivasagam, T; Paul, R; Phukan, BC, 2018) |
| "Melatonin was administered intraperitoneally at a dose of 10 mg/kg/day for 30 days in M and Mel-6-OHDA groups, for 7 days in 6-OHDA-Mel group." | 1.42 | Melatonin is protective against 6-hydroxydopamine-induced oxidative stress in a hemiparkinsonian rat model. ( Agar, A; Aslan, M; Kaya, Y; Ogut, E; Ozsoy, O; Parlak, H; Tanriover, G; Yildirim, FB, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| López, A | 1 |
| Ortiz, F | 1 |
| Doerrier, C | 1 |
| Venegas, C | 1 |
| Fernández-Ortiz, M | 1 |
| Aranda, P | 1 |
| Díaz-Casado, ME | 1 |
| Fernández-Gil, B | 1 |
| Barriocanal-Casado, E | 1 |
| Escames, G | 1 |
| López, LC | 1 |
| Acuña-Castroviejo, D | 2 |
| Paul, R | 1 |
| Phukan, BC | 1 |
| Justin Thenmozhi, A | 1 |
| Manivasagam, T | 2 |
| Bhattacharya, P | 1 |
| Borah, A | 1 |
| Naskar, A | 1 |
| Chakraborty, J | 1 |
| Singh, R | 1 |
| Thomas, B | 1 |
| Dhanasekaran, M | 1 |
| Mohanakumar, KP | 1 |
| Mattam, U | 1 |
| Jagota, A | 1 |
| Ozsoy, O | 1 |
| Yildirim, FB | 1 |
| Ogut, E | 1 |
| Kaya, Y | 1 |
| Tanriover, G | 1 |
| Parlak, H | 1 |
| Agar, A | 1 |
| Aslan, M | 1 |
| Labunets, IF | 1 |
| Talanov, SA | 1 |
| Vasilyev, RG | 1 |
| Rodnichenko, AE | 1 |
| Utko, NA | 1 |
| Kyzminova, IA | 1 |
| Kopjak, BS | 1 |
| Podjachenko, EV | 1 |
| Sagach, VF | 1 |
| Butenko, GM | 1 |
| Lin, L | 1 |
| Meng, T | 1 |
| Liu, T | 1 |
| Zheng, Z | 1 |
| Sharma, R | 1 |
| McMillan, CR | 1 |
| Tenn, CC | 1 |
| Niles, LP | 1 |
| Alvira, D | 1 |
| Tajes, M | 1 |
| Verdaguer, E | 1 |
| Folch, J | 1 |
| Camins, A | 1 |
| Pallas, M | 1 |
| Woodgate, A | 1 |
| MacGibbon, G | 1 |
| Walton, M | 1 |
| Dragunow, M | 1 |
| Absi, E | 1 |
| Ayala, A | 1 |
| Machado, A | 1 |
| Parrado, J | 1 |
| Dabbeni-Sala, F | 1 |
| Franceschini, D | 1 |
| Skaper, SD | 1 |
| Giusti, P | 1 |
| Burton, S | 1 |
| Daya, S | 1 |
| Potgieter, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Melatonin Administration on the PER1 and BMAL1 Clock Genes in Patients With Parkinson's Disease[NCT04287543] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2021-05-31 | Withdrawn (stopped due to Due to the COVID-19 pandemic, we were unable to begin the study) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
13 other studies available for melatonin and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Mitochondrial impairment and melatonin protection in parkinsonian mice do not depend of inducible or neuronal nitric oxide synthases.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Gene Expression Regulation; | 2017 |
Melatonin protects against behavioral deficits, dopamine loss and oxidative stress in homocysteine model of Parkinson's disease.
Topics: Animals; Antioxidants; Behavior, Animal; Catecholamines; Dopamine; Dopaminergic Neurons; Electron Tr | 2018 |
Melatonin synergizes with low doses of L-DOPA to improve dendritic spine density in the mouse striatum in experimental Parkinsonism.
Topics: Animals; Antiparkinson Agents; Central Nervous System Depressants; Corpus Striatum; Dendrites; Dopam | 2013 |
Daily rhythms of serotonin metabolism and the expression of clock genes in suprachiasmatic nucleus of rotenone-induced Parkinson's disease male Wistar rat model and effect of melatonin administration.
Topics: Animals; ARNTL Transcription Factors; Circadian Rhythm; CLOCK Proteins; Cryptochromes; Disease Model | 2015 |
Melatonin is protective against 6-hydroxydopamine-induced oxidative stress in a hemiparkinsonian rat model.
Topics: Animals; Catalase; Drug Evaluation, Preclinical; Free Radical Scavengers; Glutathione Peroxidase; Li | 2015 |
[THYMIC HORMONES, ANTIOXIDANT ENZYMES AND NEUROGENESIS OF BULBUS OLFACTORIUS IN RATS WITH PARKINSONISM: THE EFFECT OF MELATONIN].
Topics: Animals; Antioxidants; Apomorphine; Ataxia; Catalase; Cell Count; Cell Differentiation; Dopamine Ago | 2015 |
Increased melatonin may play dual roles in the striata of a 6-hydroxydopamine model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatography, High Pressure Liquid; Corpus Striatum; Data | 2013 |
Physiological neuroprotection by melatonin in a 6-hydroxydopamine model of Parkinson's disease.
Topics: Animals; Apomorphine; Brain-Derived Neurotrophic Factor; Densitometry; Dopamine Agonists; Functional | 2006 |
Inhibition of the cdk5/p25 fragment formation may explain the antiapoptotic effects of melatonin in an experimental model of Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; Calpain; Caspase 3; Caspases; Cell Survival; Cells, | 2006 |
The toxicity of 6-hydroxydopamine on PC12 and P19 cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Aurintricarboxylic Acid; Biological Transport; Bisbenzimi | 1999 |
Protective effect of melatonin against the 1-methyl-4-phenylpyridinium-induced inhibition of complex I of the mitochondrial respiratory chain.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Corpus Striatum; Electron Transport Complex I; Humans; In Vitr | 2000 |
Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity.
Topics: Adenosine Triphosphatases; Animals; Apomorphine; Behavior, Animal; Disease Models, Animal; Electron | 2001 |
Melatonin modulates apomorphine-induced rotational behaviour.
Topics: Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Hun | 1991 |